



- (51) **International Patent Classification:**  
*C07K 14/705* (2006.01) *C07K 16/22* (2006.01)
- (21) **International Application Number:**  
PCT/IB2017/057436
- (22) **International Filing Date:**  
28 November 2017 (28.11.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
1620119.6 29 November 2016 (29.11.2016) GB
- (71) **Applicant:** PHARMAFOX THERAPEUTICS AG  
[CH/CH]; Untere Fuchsrainstrasse 16, CH-4313 Möhlin  
(CH).
- (72) **Inventors:** VRIJBLOED, Jan Willem; Untere Fuchsrainstrasse 16, CH-4313 Möhlin (CH). BIDO, Marina Maria; V. Fratelli Cervi 13, 10042 Nichelino (TO) (IT). BUTENKO, Olena; Humpolecka 1938/8, 14000 Prague (CZ). SCHELLINO, Roberta; Via Gareggio 33/2, 10126 Torino (IT).
- (74) **Agent:** MCSTEA, John Anthony; Teemacs GmbH, Kantonsstrasse 7, CH-4416 Bubendorf (CH).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

- (54) **Title:** MUSCLE PERFORMANCE IMPROVEMENT COMPOUNDS




Figure 1

- (57) **Abstract:** A compound comprising at least two components, a first component being the nLG3 domain from the C-terminus of human agrin, and at least one second component, selected from proteins or an antagonistic antibody that inhibit ActR2B-induced signaling activity in the presence of myostatin, the components being linked by means of linking entities. Such compounds are effective treatments for neuromuscular diseases and problems.

[Continued on next page]

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))